Key facts
- Progentec’s last known valuation is $30.0M (Jun 2020).
- It has raised $7.5M; the latest was Later Stage VC in May 2025.
- Notable investors include Mayo Clinic, Mayo Clinic Ventures, Leland Stanford Junior University, Stanford University Venture Fund, NMC Healthcare — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Progentec
- ·The full record, as it builds
Funding rounds
No funding rounds for Progentec are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Progentec
Developer of diagnostics and digital therapeutics platform designed to manage autoimmune diseases. The company combines clinically validated diagnostic interventions with digital technologies and collaborates with research institutions and health practitioners to reduce mortality and morbidity, enabling chronic health patients to have improved care management and service delivery.
- Sector
- Healthcare
- HQ
- Oklahoma City, OK, United States
- Founded
- 2015
- Employees
- 16
- Website
- progentec.com/
- Ownership
- Privately Held (backing)
Progentec doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Progentec shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Progentec in its N-PORT filings yet. We sweep new filings monthly.